Carron Layfield
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Carron Layfield has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Hywel Williams
Centre of Evidence-Based Dermatology, Lifespan and Population Health, School of Medicine, University of Nottingham , Nottingham
2 shared publications Aaron Foulds
Citizen Scientist
1 shared publication- Alan A. Montgomery
University of Nottingham
1 shared publication - Amanda Roberts
Centre of Evidence Based Dermatology, School of Medicine, University of Nottingham , Nottingham
1 shared publication - Arabella Baker
Centre of Evidence Based Dermatology, School of Medicine, University of Nottingham, Nottingham, UK
1 shared publication Devin Patel
Citizen Scientist
1 shared publication
Latest Publications
- Open Access
- 31 March 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (9) , 1611-1620
Identifying characteristics of people with bullous pemphigoid prior to diagnosis using clustering analysis: a UK population-based case–control study
Background: Bullous pemphigoid (BP) is a rare, serious autoimmune skin disease that is more common in older people. Numerous drugs and conditions have been previously associated with BP, but no study has explored patterns of risk factors. It is important to identify characteristics of people at risk of BP to help raise clinical suspicion. Diagnostic delay can lead to serious symptoms and poor quality of life. Objectives: To identify patterns of drug prescriptions, comorbidities and sociodemographic characteristics of people with BP prior to diagnosis. Methods: We conducted a 1 : 1 case–control study (1998–2021) using routinely collected primary care data from the Clinical Practice Research Datalink. Cases were matched to controls by age, sex and clinical practice. We ran clustering analysis to identify groups of cases with similar characteristics. We repeated the analysis for controls to verify whether these characteristics are unique or more common in cases. Results: There were 16 624 cases and 16 624 controls (median age 80 years; 55.6% women). Eight case/control clusters were identified. Four case clusters included people who were all prescribed penicillinase-resistant penicillins. Statins were prescribed in six BP and four control clusters. Multiple sclerosis was rare (1–2% of people) but unique in case clusters (five of eight). Conclusions: Penicillinase-resistant penicillins and statins were more often prescribed prior to BP diagnosis. Healthcare professionals should be vigilant for skin reactions in older people following these medications, particularly penicillinase-resistant penicillins. Due to low BP prevalence, we do not suggest preventative discontinuation of highlighted drugs. We also propose checking for skin reactions following a multiple sclerosis diagnosis.
- 31 March 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (9) , 1611-1620
Open AccessIdentifying characteristics of people with bullous pemphigoid prior to diagnosis using clustering analysis: a UK population-based case–control study
Background: Bullous pemphigoid (BP) is a rare, serious autoimmune skin disease that is more common in older people. Numerous drugs and conditions have been previously associated with BP, but no study has explored patterns of risk factors. It is important to identify characteristics of people at risk of BP to help raise clinical suspicion. Diagnostic delay can lead to serious symptoms and poor quality of life. Objectives: To identify patterns of drug prescriptions, comorbidities and sociodemographic characteristics of people with BP prior to diagnosis. Methods: We conducted a 1 : 1 case–control study (1998–2021) using routinely collected primary care data from the Clinical Practice Research Datalink. Cases were matched to controls by age, sex and clinical practice. We ran clustering analysis to identify groups of cases with similar characteristics. We repeated the analysis for controls to verify whether these characteristics are unique or more common in cases. Results: There were 16 624 cases and 16 624 controls (median age 80 years; 55.6% women). Eight case/control clusters were identified. Four case clusters included people who were all prescribed penicillinase-resistant penicillins. Statins were prescribed in six BP and four control clusters. Multiple sclerosis was rare (1–2% of people) but unique in case clusters (five of eight). Conclusions: Penicillinase-resistant penicillins and statins were more often prescribed prior to BP diagnosis. Healthcare professionals should be vigilant for skin reactions in older people following these medications, particularly penicillinase-resistant penicillins. Due to low BP prevalence, we do not suggest preventative discontinuation of highlighted drugs. We also propose checking for skin reactions following a multiple sclerosis diagnosis.
- Open Access
- 10 November 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (3) , 450-460
Weekly versus daily bathing for people with eczema: results of the Eczema Bathing online randomized controlled trial
Background: Questions about washing are a high priority for people with eczema (also known as atopic dermatitis and atopic eczema), but they are rarely the focus of randomized controlled trials (RCTs). Objectives: To assess the impact of weekly vs. daily bathing in people with eczema in the first of a series of eczema citizen science online trials in the UK. Methods: This was a pragmatic two-arm parallel-group superiority RCT. People with self-reported eczema aged ≥ 1 years were eligible, excluding those with very mild eczema [Patient Orientated Eczema Measure (POEM) score ≤ 2]. Participants were allocated (1 : 1) using minimization, balancing on eczema severity (POEM), age and usual method of bathing to either the weekly bathing group (bath or shower once or twice weekly) or the daily bathing group (bath or shower ≥ 6 times weekly) for 4 weeks. Participants were not blinded to their allocation. The primary outcome was participant-reported eczema symptoms collected weekly over 4 weeks using POEM (range 0–28, where higher scores indicate more severe eczema). The trial was registered with ISRCTN on 22 November 2023 (https://www.isrctn.com/ISRCTN12016473). Results: In total, 438 people with eczema (108 of whom were aged < 16 years) were randomized between 29 January and 8 July 2024: 218 to daily bathing and 220 to weekly bathing. The primary analysis included 195 participants (89.4%) allocated to daily bathing and 193 (87.7%) to weekly bathing who completed at least one follow-up questionnaire. Mean (SD) POEM scores at baseline and at 1, 2, 3 and 4 weeks were 14.5 (5.7), 11.7 (5.9), 12.2 (5.9), 11.7 (6.7) and 11.6 (6.5), respectively, in the daily bathing group and 14.9 (6.3), 12.1 (6.8), 11.3 (6.7), 10.5 (7.0) and 10.6 (7.2), respectively, in the weekly bathing group. The adjusted difference in mean POEM score over 4 weeks for weekly vs. daily bathing was –0.4 (95% confidence interval –1.3 to 0.4; P = 0.30). Process evaluation data highlighted participants’ experiences of making changes to bathing routines, including barriers to following the allocated routine. No serious unintended effects or harms were reported. Conclusions: The trial found no evidence of a difference in eczema symptoms between bathing or showering weekly vs. daily. These results are helpful for people with eczema, giving them the freedom to choose what suits them best.
- 10 November 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (3) , 450-460
Open AccessWeekly versus daily bathing for people with eczema: results of the Eczema Bathing online randomized controlled trial
Background: Questions about washing are a high priority for people with eczema (also known as atopic dermatitis and atopic eczema), but they are rarely the focus of randomized controlled trials (RCTs). Objectives: To assess the impact of weekly vs. daily bathing in people with eczema in the first of a series of eczema citizen science online trials in the UK. Methods: This was a pragmatic two-arm parallel-group superiority RCT. People with self-reported eczema aged ≥ 1 years were eligible, excluding those with very mild eczema [Patient Orientated Eczema Measure (POEM) score ≤ 2]. Participants were allocated (1 : 1) using minimization, balancing on eczema severity (POEM), age and usual method of bathing to either the weekly bathing group (bath or shower once or twice weekly) or the daily bathing group (bath or shower ≥ 6 times weekly) for 4 weeks. Participants were not blinded to their allocation. The primary outcome was participant-reported eczema symptoms collected weekly over 4 weeks using POEM (range 0–28, where higher scores indicate more severe eczema). The trial was registered with ISRCTN on 22 November 2023 (https://www.isrctn.com/ISRCTN12016473). Results: In total, 438 people with eczema (108 of whom were aged < 16 years) were randomized between 29 January and 8 July 2024: 218 to daily bathing and 220 to weekly bathing. The primary analysis included 195 participants (89.4%) allocated to daily bathing and 193 (87.7%) to weekly bathing who completed at least one follow-up questionnaire. Mean (SD) POEM scores at baseline and at 1, 2, 3 and 4 weeks were 14.5 (5.7), 11.7 (5.9), 12.2 (5.9), 11.7 (6.7) and 11.6 (6.5), respectively, in the daily bathing group and 14.9 (6.3), 12.1 (6.8), 11.3 (6.7), 10.5 (7.0) and 10.6 (7.2), respectively, in the weekly bathing group. The adjusted difference in mean POEM score over 4 weeks for weekly vs. daily bathing was –0.4 (95% confidence interval –1.3 to 0.4; P = 0.30). Process evaluation data highlighted participants’ experiences of making changes to bathing routines, including barriers to following the allocated routine. No serious unintended effects or harms were reported. Conclusions: The trial found no evidence of a difference in eczema symptoms between bathing or showering weekly vs. daily. These results are helpful for people with eczema, giving them the freedom to choose what suits them best.
- Open Access
- 13 April 2022
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 47 (6) , 1060-1067
Celebrating 20 years of the UK Dermatology Clinical Trials Network. Part 2: education, training and capacity building
In part 1 of this 2-part review of the 20th anniversary of the UK Dermatology Clinical Trials Network (UK DCTN), we described its role in developing and supporting clinical trial proposals, elaborating on structure, process and clinical trials activity. This review describes the diverse educational and training activities that the UK DCTN supports. Although not primarily set up as an educational organisation, an education and training function emerged organically as the network grew. Education and training also embodies the democratisation principle that drove the formation of the UK DCTN, allowing participation from a much wider group of individuals than just senior academics. Far from being a side-line, education and training has now become a major component of the UK DCTN that evolves constantly through changing training curricula and trial methodology developments. Formal UK DCTN training opportunities started in 2007 with competitively awarded annual fellowships for dermatology trainees, followed by similar schemes for general practitioners, Staff and Associate Specialist clinicians, and dermatology nurses. These were followed in 2013 by larger groups of trainees who work up specific trial proposals with senior mentors. Finally, a virtual journal club emerged during the pandemic in 2020 in order to reach trainees with little access to academic training. Focused activities with dermatological nurses and patients/carers also take place. Such activities require considerable organisation and volunteerism from the co-ordinating centre and former fellows. Education and training has become an essential component for capacity building to develop clinical trials and succession planning for the UK DCTN.
- 13 April 2022
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 47 (6) , 1060-1067
Open AccessCelebrating 20 years of the UK Dermatology Clinical Trials Network. Part 2: education, training and capacity building
In part 1 of this 2-part review of the 20th anniversary of the UK Dermatology Clinical Trials Network (UK DCTN), we described its role in developing and supporting clinical trial proposals, elaborating on structure, process and clinical trials activity. This review describes the diverse educational and training activities that the UK DCTN supports. Although not primarily set up as an educational organisation, an education and training function emerged organically as the network grew. Education and training also embodies the democratisation principle that drove the formation of the UK DCTN, allowing participation from a much wider group of individuals than just senior academics. Far from being a side-line, education and training has now become a major component of the UK DCTN that evolves constantly through changing training curricula and trial methodology developments. Formal UK DCTN training opportunities started in 2007 with competitively awarded annual fellowships for dermatology trainees, followed by similar schemes for general practitioners, Staff and Associate Specialist clinicians, and dermatology nurses. These were followed in 2013 by larger groups of trainees who work up specific trial proposals with senior mentors. Finally, a virtual journal club emerged during the pandemic in 2020 in order to reach trainees with little access to academic training. Focused activities with dermatological nurses and patients/carers also take place. Such activities require considerable organisation and volunteerism from the co-ordinating centre and former fellows. Education and training has become an essential component for capacity building to develop clinical trials and succession planning for the UK DCTN.